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Abstract
Background—The pathogenesis of inflammatory bowel disease (IBD) is complex and the need
to identify molecular biomarkers is critical. Epithelial cells play a central role in maintaining
intestinal homeostasis. We previously identified 5 “signature” biomarkers in colonic epithelial
cells (CEC) that are predictive of disease phenotype in Crohn’s disease. Here we investigate the
ability of CEC biomarkers to define the mechanism and severity of intestinal inflammation.
Methods—We analyzed expression of RelA, A20, pIgR, TNF and MIP-2 in CEC of mice with
DSS acute colitis or T cell-mediated chronic colitis. Factor analysis was used to combine the 5
biomarkers into 2 multifactorial principal components (PCs). PC scores for individual mice were
correlated with disease severity.
Results—For both colitis models, PC1 was strongly weighted toward RelA, A20 and pIgR, and
PC2 was strongly weighted toward TNF and MIP-2, while the contributions of other biomarkers
varied depending on the etiology of inflammation. Disease severity was correlated with elevated
PC2 scores in DSS colitis and reduced PC1 scores in T cell transfer colitis. Down-regulation of
pIgR was a common feature observed in both colitis models and was associated with altered
cellular localization of pIgR and failure to transport IgA.
Conclusions—A multifactorial analysis of epithelial gene expression may be more informative
than examining single gene responses in IBD. These results provide insight into the homeostatic
and pro-inflammatory functions of CEC in IBD pathogenesis and suggest that biomarker analysis
could be useful for evaluating therapeutic options for IBD patients.
Keywords
colonic epithelial cell; polymeric immunoglobulin receptor; experimental colitis; inflammatory
bowel disease; gene expression; biomarkers
INTRODUCTION
Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis
(UC), are thought to result from inappropriate inflammatory responses to normal
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components of the intestinal microbiota in genetically susceptible individuals1–3. Recent
evidence has implicated both ineffective innate immune responses and overactive adaptive
immune responses in the pathogenesis of IBD1, 2, 4–10. Colonic epithelial cells (CEC) bridge
innate and adaptive immune responses through cross-talk with luminal bacteria and with
lamina propria immune cells1, 2, 6. There is a critical need to identify cellular and molecular
biomarkers that can predict disease behavior and guide personalized therapy, and a number
of candidates have been proposed11–15. Considering the complex etiology and the
heterogeneous clinical presentation of IBD, we propose that a multifactorial approach offers
significant advantages over the use of single biomarkers for diagnosis and treatment of IBD.
Our group recently identified signature biomarkers in the colonic mucosa of CD patients that
could be used in a multifactorial analysis to classify patients into molecular phenotypic
subsets that were predictive of clinical characteristics and responses to therapy16. These
biomarkers comprised 5 genes: the RelA subunit of NF-κB; A20, a ubiquitin-modifying
enzyme that negatively regulates the NF-κB activation pathway; the polymeric
immunoglobulin receptor (pIgR), which mediates epithelial transcytosis of IgA antibodies;
the pro-inflammatory cytokine tumor necrosis factor (TNF), and the pro-inflammatory
chemokine interleukin (IL)-8. The aim of the present study was to define patterns of
biomarker gene expression that reflect the underlying mechanism and severity of intestinal
inflammation. To this end we utilized two mouse models of colitis with very different
etiologies. Oral administration of dextran sulfate sodium (DSS) induces acute colitis that is
mediated primarily by effectors of innate immunity and causes damage to the epithelial
barrier17. In contrast, adoptive transfer of naïve T cells into immunodeficient mice causes
chronic colitis initiated by effector T cells and characterized by epithelial hyperplasia, goblet
cell depletion and transmural inflammation18–21. We found different patterns of biomarker
expression in these two models of experimental colitis that were predictive of disease
severity. Importantly, down-regulation of expression and altered cellular localization of
pIgR was a common feature of both colitis models. Furthermore, these defects were
associated with failure to transport IgA. These results provide insights into the functions of
CEC in regulation of intestinal inflammation, and provide proof of principle for the use of
principal component analysis in the molecular diagnosis of intestinal inflammation.
MATERIALS AND METHODS
Animals
Six-week old female wild-type C57BL/6 and 8-week old female Rag1−/− C57BL/6 mice
were purchased from the Jackson Laboratories (Bar Harbor, ME). Mice were housed in
microisolator cages with sterile bedding, food and water in AAALAC-accredited facility.
All procedures were conducted in accordance with guidelines set forth by the University of
Kentucky Institutional Animal Care and Use Committee.
DSS Model of Acute Colitis
Acute colitis was induced by oral administration of dextran sulfate sodium (DSS), as
described 22. DSS (molecular weight 36,000 –50,000; MP Biomedicals, Aurora, OH) was
dissolved in water at indicated concentration and given ad libitum to mice for 8 days in
place of normal drinking water. Water intake was measured daily to ensure consistency in
DSS intake among mice. A disease activity index (DAI) was calculated daily for each mouse
during DSS treatment, on a 0–4 scale that assessed weight loss, stool consistency, and fecal
blood (visible and occult), as described 23. ColoScreen-ES testing kits (Helena Laboratories,
Beaumont, TX) were used to detect occult blood.
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T cell Transfer Model of Chronic Colitis
Chronic colitis was induced by adoptive transfer of naïve T cells from wild-type mice into
Rag1−/− recipients, which lack B and T lymphocytes, as described19. To purify T-effector
(Teff) and T-regulatory (Treg) cell populations for adoptive transfer, single cell suspensions
from spleens of 10 week-old wild-type C57BL/6 mice were prepared in phosphate-buffered
saline with 4% fetal bovine serum. In two of the three independent experiments,
CD4+CD45RBhi and CD4+CD45RBlo cell populations were isolated by fluorescence-
activated cell sorting. Spleen cells were labeled with anti-CD4 antibodies (eBiosciences, San
Diego CA) and anti-CD45RB (Biolegend, San Diego CA) and sorted into CD4+CD45RBhi
(as a source of Teff) and CD4+CD45RBlo fractions (as a source of natural Treg), defined as
the uppermost 30% of cells with the brightest CD45RB staining and the lowest 15% of cells
with the dimmest CD45RB expression, respectively (Supporting Fig. 1A). The Teff and
Treg fractions were subsequently demonstrated to differ dramatically in cell surface
expression of CD25, a marker for natural Treg (Supporting Fig. 1B). In one of the three
independent experiments, CD4+ splenic T cells were separated into CD25− (Teff) andCD25+
(Treg) populations by magnetic bead sorting using the Regulatory T cells kit (Miltenyi,
Auburn CA). Nine-week-old Rag1−/− C57BL/6 mice received a single intraperitoneal
injection of 4 × 105 purified Teff, with or without 1 × 105 purified Treg. Following adoptive
transfer, body weight was monitored every 3 days and mice were sacrificed at 10 weeks
post-transfer. No significant differences were observed in clinical parameters, tissue
histology or colonic EC gene expression that could be attributed to the different methods of
purification of Teff and Treg populations (immunofluorescence vs. magnetic beads).
Tissue Histology
Colons were dissected from euthanized mice and the length of the colon from the anus to the
cecal junction was measured. For T cell transfer colitis, colons were weighed and the
weight/length ratio was calculated. Colons were cut lengthwise, and half of each colon was
prepared in a “Swiss roll”24 and fixed in 10% buffered formalin (Fisher Scientific, Fair
Lawn, NJ). Fixed tissues were embedded in paraffin, sectioned, stained with hematoxylin
and eosin, and evaluated in a blinded fashion for evidence of inflammation and epithelial
damage. For DSS-induced colitis, tissue damage was quantified on a scale from 0–4 as
previously described29, using the following criteria: 0, no change from normal tissue; grade
1, mild inflammation present in the mucosa, comprised mainly of mononuclear cells, with
little epithelial damage; grade 2, multifocal inflammation greater than a grade 1 score,
including mononuclear cells and some neutrophils, detachment of crypt glands from the
muscularis mucosae, mucin depletion from goblet cells, and occasional detachment of the
epithelium from the mucosa; grade 3, multifocal inflammation greater than a grade 2 score,
including mononuclear cells and neutrophils infiltrating the submucosa, crypt abscesses
present with increased mucin depletion, and significant epithelial disruption, including some
ulceration; grade 4, crypts no longer present, severe mucosal inflammation mainly
composed of neutrophils, and epithelium no longer present or completely detached. For T
cell transfer colitis, tissue damage was quantified by combining the scores for each of the
following parameters for a maximum score of 17: degree of inflammation in the lamina
propria (score 0–3); goblet cell loss (score 0–3); abnormal crypts (score 0–3); presence of
crypt abscesses (score 0–1); mucosal erosion and ulceration (score 0–1); transmural
involvement (score 0–3); and number of neutrophils counted at 40x magnification (score 0–
3). For both models of colitis, an average of 4 fields of view per colon were evaluated for
each mouse to obtain a composite score.
Colonic Epithelial Cell Isolation
CEC were isolated as previously described 25. Colons were opened longitudinally, cut into 1
mm pieces, and the mucus layer was removed by incubation for 20 min with agitation at
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37°C in a solution of 1mM dithiothreitol (Sigma, St. Louis MO) in DMEM:Ham’s F-12
(1:1) tissue culture medium (Lonza, Walkersville MD), supplemented with 5% fetal bovine
serum and antibiotics (100 U/ml penicillin, 100 μg/ml streptomycin, and 250 ng/ml
fungizone) (Invitrogen Life Technologies, Carlsbad CA). The supernatants were discarded,
and CEC were stripped from the colon pieces by incubation for 1 h at 37°C in a solution of
0.5 M EDTA in supplemented tissue culture media. The suspension was vortexed
vigorously, and the remaining colon fragments were allowed to settle at the bottom of the
flask. The upper layers were centrifuged at 2000 rpm for 10 minutes at 4°C to collect ECs.
Further purification of the CEC fraction was accomplished by resuspension of the cell
pellets in a 10 ml solution of 30% w/v Percoll (Sigma) and centrifugation at 1300 rpm for 20
min at room temperature. The top layer containing floating CEC was removed and
transferred into a 15 ml conical tube. The volume was brought to 10 ml with supplemented
tissue culture medium, and the CEC solution was pelleted by centrifugation at 2000 rpm for
10 min at 4°C. CEC viability, assessed by trypan blue exclusion, was typically > 90 %. Flow
cytometry analysis of representative CEC preparations indicated that contamination with
CD45+ hematopoietic cells was approximately 0.4 % for control mice and 1.3 % for DSS-
treated mice (Supporting Fig. 2).
Analysis of mRNA Levels by Real-time PCR
mRNA levels for individual genes were analyzed by quantitative reverse transcriptase-
polymerase chain reaction (qRT-PCR) as previously described26. Total RNA was purified
from isolated CEC using the Qiagen RNeasy Protect mini kit (Qiagen, Germantown MD).
RNA was reverse-transcribed to generate cDNA templates using the TaqMan Gold RT-PCR
kit (Applied Biosystems, Foster City, CA). Specific mRNA levels were quantified by
quantitative real-time polymerase chain reaction, using the ABI Prism 7700 Sequence
Detection System (Applied Biosystems) as previously described26. The level of β2-
microglobulin mRNA, which we found did not vary with experimental treatments, was used
to normalize mRNA for tested genes according to the following formula:
(2−(CT test – CT β2-microglobulin)) × 100%.
Immunofluorescence microscopy
Sections of formalin-fixed, paraffin-embedded colon tissues were dewaxed and rehydrated
using standard protocols. Antigen retrieval was performed by incubating slides for 20 min at
95°C in 25 ml of 10 mM sodium citrate buffer, pH 6. Endogenous peroxidase activity was
quenched by incubation for 10 min at room temperature in 25 ml of 3% (v/v) H202. Cell-
associated pIgR and free secretory component (the cleaved extracellular domain of pIgR)
were detected by overnight incubation of tissue sections at 4°C with a polyclonal goat
antibody to mouse secretory component (2.5 μg/ml) (R&D Systems, Minneapolis, MN).
Sections were washed with PBS and incubated for 30 min at room temperature with a
horseradish peroxidase-conjugated rabbit antibody to goat IgG (1μg/ml) (Invitrogen,
Camarillo CA). Bound peroxidase was revealed with TSA Plus-TMR Reagent (Perkin-
Elmer, Waltham MA). IgA was detected in the same tissue sections by subsequent
incubation for 1 hour at room temperature with FITC-conjugated antibody to mouse IgA
(1μg/ml) (eBiosciences, San Diego CA). All antibodies were diluted in Blocking Reagent
(Perkin-Elmer). Sections were mounted with VectaShield (Vector Laboratories, Burlingame
CA) containing DAPI to visualize nuclei. Stained tissue sections were imaged on a Zeiss
Axiophot confocal microscope with Axiovision image software.
Statistical Analysis
Statistical differences in disease parameters and mRNA levels among treatment groups were
determined by analysis of variance and Fisher’s protected least significant difference test.
Correlation Z test was used to test for correlations among mRNA levels for different
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biomarkers. Factor analysis was used to reduce the 5 mRNA biomarkers into two principal
components (PCs), as previously described 27. To assign scores for PC1 and PC2, the
mRNA level for each of the 5 biomarkers for each mouse was first normalized to the mean
for that biomarker for all mice within the DSS protocol or the T cell transfer protocol.
Individual scores for PC1 and PC2 were calculated as the sum of the normalized value for
each biomarker multiplied by the weight for that biomarker. Linear regression analysis was
used to compare PC1 or PC2 values with % initial weight, colon length or the ratio of colon
weight/length, and histological score. All statistical analyses were performed using StatView
Software (SAS Institute, Cary, NC).
RESULTS
Assessment of disease severity in DSS and T cell-mediated colitis
Acute colitis induced by oral administration of DSS resulted in significant weight loss,
disease activity (diarrhea and blood loss) and pathological findings (colon shortening), with
more severe symptoms in mice administered 3% DSS than 2% DSS (Fig. 1A,B). Tissue
damage, including edema, goblet cell loss, ulcerations, epithelial cell destruction, and
infiltration of inflammatory cells, was observed in all DSS-treated mice and was more
severe in mice treated with 3% DSS (Fig. 1C). Chronic colitis induced by adoptive transfer
of CD4+CD45RBhiCD25− Teff cells into Rag1−/− recipients resulted in a different clinical
picture involving weight loss and an increased ratio of colon weight/length (Fig. 1D,E), but
no symptoms of acute colitis such as diarrhea or blood loss (data not shown). Co-
administration of CD4+CD45RBloCD25+ Treg with Teff corrected the clinical symptoms of
T cell-mediated colitis. Interestingly, colon tissues from control Rag1−/− mice exhibited a
significantly shorter epithelial crypt length than did wild-type mice (compare Fig. 1B and
1E) suggesting that the absence of B and T lymphocytes impaired normal development of
the colonic epithelium. Adoptive transfer of Teff, with or without Treg, resulted in extensive
crypt lengthening (Fig. 1F). Histological evidence of Teff-mediated colitis included
infiltration of lymphocytes and mononuclear cells into both the mucosa and submucosa, but
fewer neutrophils. Some mucosal edema and epithelial damage was observed, but this was
less severe than in acute DSS-mediated colitis mice (compare Fig. 1C and 1F). Co-
administration of Treg with Teff resulted in a moderate reduction in the inflammatory
infiltrate and lessened epithelial damage and mucosal edema.
Differential expression of “signature” biomarkers in colonic epithelial cells in acute DSS-
mediated and chronic T cell-mediated colitis
We used these different models of experimental colitis to examine the relationship between
the etiology of intestinal inflammation and gene expression in colonic ECs. RNA was
extracted from isolated ECs, and levels of mRNA were analyzed for 5 “signature”
biomarkers that we have used to classify IBD patients into molecular phenotypic subsets 16,
i.e., RelA, A20, pIgR, TNF and MIP-2 (a functional homolog of human IL-8) (Figure 2).
While the overall patterns of biomarker expression varied considerably between DSS and T
cell-mediated colitis, the one common feature was down-regulation of pIgR mRNA.
Interestingly, co-administration of Treg with Teff prevented down-regulation of pIgR. These
data are consistent with the notion that mucosal inflammation, independent of its cause, is
sufficient to impair normal expression of pIgR. By contrast, down-regulation of the RelA
subunit of NF-κB was a more consistent feature of T cell-mediated colitis than DSS colitis.
Down-regulation of RelA in mice adoptively transferred with Teff was correlated with
reduced expression of A20, a RelA target gene that is induced by the classical NF-κB
pathway and acts as a negative feedback regulator of NF-κB activation 28. Co-
administration of Treg with Teff did not restore RelA mRNA to control levels, but was
sufficient to prevent down-regulation of A20. Finally, acute DSS colitis was characterized
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by strong up-regulation of the pro-inflammatory genes TNF and MIP-2 in CEC, which was
not seen in chronic T cell-mediated colitis.
Multifactorial patterns of biomarker expression predict disease phenotype
It is clear that synergistic interactions among multiple gene products are involved in
inflammatory responses, thus we used a multifactorial approach to identify patterns of gene
expression that are associated with different etiologies of colitis. Factor analysis by the
principal component (PC) method is a statistical approach that is used to reduce the number
of variables in a complex data set and to classify relationships between those variables. We
previously used PC analysis, based on the 5 “signature” biomarkers described in Figure 2, to
classify CD patients into molecular phenotypic subsets that were predictive of clinical
disease 16. Here we demonstrate different patterns of gene expression associated with DSS
and T cell-mediated experimental colitis in mice (Fig. 3). Chi-square analysis indicated that
variability in the gene expression data sets for both DSS colitis and T cell transfer colitis
could be reduced to two PCs (p < 0.0001) (Fig. 3A). Eigen values indicated that the
proportion of variance among mice in expression of these 5 variables that could be described
by PC1 and PC2 together was 72.5% for DSS colitis and 75.1% for T cell transfer colitis.
The coefficients for each variable describe its relative contribution to PC1 and PC2. For both
DSS colitis and T cell transfer colitis, PC1 was strongly weighted toward RelA, A20 and
pIgR, with a negative weight for MIP-2. Interestingly, TNF had a minimal contribution to
PC1 for DSS colitis, but contributed strongly to PC1 for T cell transfer colitis. PC2 was
strongly weighted toward TNF and MIP-2 for both DSS colitis and T cell colitis. The
relative contributions of RelA and A20 to PC2 differed for the two models, and pIgR did not
contribute significantly to PC2 for either model. We conclude that the different patterns of
epithelial gene expression reflect the different etiologies of DSS and T cell-mediated colitis
and may be useful for predicting disease phenotype. To this end, each mouse was assigned a
score for PC1 and PC2 based on the sum of the weighted expression levels for all 5
biomarkers (see Materials and Methods for details) (Fig. 3B). For the DSS model, PC1
scores did not vary significantly among treatment groups, whereas the score for PC2
increased significantly with increasing DSS dose. Interestingly, the opposite pattern held for
T cell transfer colitis. Adoptive transfer with Teff resulted in a significantly lower PC1
score, which was prevented by co-administration of Treg, whereas no significant differences
in PC2 scores were observed.
To investigate whether these multifactorial PCs could predict disease severity, we performed
linear regression analysis to examine the relationship between PC1 and PC2 scores and
clinical measures of disease (Fig. 4). In the DSS colitis model, increased PC2 scores were
significantly correlated with weight loss, decreased colon length (a measure of disease
severity in DSS colitis),29 and tissue damage (quantified by histological score). A different
pattern was observed for the T cell transfer colitis model, in which decreased PC1 scores
were significantly correlated with weight loss and an increased ratio of colonic weight/
length (a measure of disease severity in T cell transfer colitis). 18, 19 However, tissue
damage in this model was significantly correlated with increased PC2 scores, similar to the
pattern seen in DSS-induced colitis. Taken together, these results suggest that a
multifactorial approach combining the expression of multiple biomarkers in colonic EC can
be used to discriminate among different mechanisms of inflammation and to predict disease
severity.
Colonic inflammation results in altered localization of pIgR and reduced epithelial
transcytosis of IgA
We previously reported that expression of pIgR and epithelial transcytosis of IgA were
dysregulated in the colonic mucosa of Crohn’s disease patients16. Because down-regulation
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of pIgR mRNA in CEC was a common feature of both DSS and T cell-mediated colitis (Fig.
2A,B), we hypothesized that epithelial transcytosis of IgA would also be altered.
Visualization of pIgR and IgA in sections of colonic tissue revealed reduced expression and
aberrant localization of pIgR in the colonic epithelium in both DSS-induced (Fig. 5A) and T
cell-mediated colitis (Fig. 5B). In untreated wild-type mice (Fig. 5A, left panel), pIgR
expression was abundant and predominantly localized to the lower two-thirds of the
epithelial crypts. Significant co-localization of pIgR and IgA was observed, consistent with
normal transcytosis of IgA. However, in the colons of DSS-treated mice, pIgR staining was
clearly reduced, consistent with reduced pIgR mRNA levels (Fig. 2A), and was not
concentrated in the lower section of the crypts. Importantly, we also observed less co-
localization of IgA and pIgR in DSS-treated mice, although the presence of IgA-producing
plasma cells in the lamina propria was increased. Similar to wild-type mice, pIgR was
predominantly localized to the lower two-thirds of the epithelial crypts in control Rag1−/−
mice (Fig. 5B). No IgA was detected in the colons of these mice, since they lack B cells and
cannot produce IgA. Total pIgR staining was markedly reduced in the Rag1−/− mice
adoptively transferred with Teff, consistent with down-regulation of pIgR mRNA (Fig. 2B),
and concentration of pIgR in the lower section of the crypts was not seen. Expression of
pIgR was substantially restored when Treg cells were co-transferred with Teff (Fig. 5B),
consistent with the restoration of pIgR mRNA levels (Fig. 2B). However, concentration of
pIgR localization in the lower section of the crypts was not fully restored.
DISCUSSION
Molecular classification of IBD patients based on multifactorial patterns of biomarker
expression offers the potential to personalize diagnosis and clinical management of this
chronic and debilitating disease. Experimental mouse models of IBD have proven to be
valuable tools for investigating mechanisms of IBD pathogenesis and for identifying
potential therapeutic targets17, 30. Oral administration of DSS causes concentration- and
time-dependent cytotoxicity of intestinal epithelial cells, thus disrupting intestinal barrier
function31. Because acute colitis could be induced by DSS in mice with severe combined
immunodeficiency, which lack B and T lymphocytes32, it has long been thought that
intestinal inflammation in this model is driven mainly by innate immune responses.
However, more recent studies comparing DSS-induced colitis in immunodeficient and wild-
type mice suggested that the presence of lymphocytes may exacerbate inflammation,
particularly at low doses of DSS33. In the T cell transfer model, chronic colitis develops as a
result of enteric antigen-driven activation, polarization and homeostatic expansion of naïve
T cells to produce colitogenic Th1 and/or Th17 effectors cells17,18. Co-administration of T
regulatory cells with T effector cells prevents induction of colitis, verifying a significant
protective role for T regulatory cells in IBD pathogenesis19, 34.
Here we have focused on a limited set of 5 “signature” epithelial biomarkers that we
previously validated for prediction of disease severity in CD patients16. Given the
heterogeneous clinical presentation in IBD, it is likely that a classification scheme based on
multiple biomarkers will be more informative than the use of individual biomarkers. It is
clear that the expression of many genes may change during intestinal inflammation.
However, by focusing on only 5 highly informative genes, we have provided proof of
principle that a multifactorial approach can transform a limited amount of data into a
potentially powerful diagnostic tool. We have now identified distinctive expression patterns
of these 5 biomarkers expression in two models of experimental colitis with different
etiologies (Fig. 2). Principal component analysis reduced the 5 biomarkers into 2
multifactorial PCs that were specific for each model (Fig. 3) and were predictive of disease
severity (Fig. 4). We propose that PC1 is a composite biomarker reflecting homeostatic
epithelial barrier function, characterized by NF-κB-stimulated physiological inflammation.
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The individual biomarkers RelA, A20 and pIgR were dominant contributors to PC1 in both
colitis models. We previously reported that high expression of PC1 was associated with mild
disease activity and good responses to therapy in CD patients16. We found that high
expression of pIgR was correlated with robust epithelial transcytosis of IgA. While
excessive NF-κB signaling in immune cells has been implicated as a major contributor to
intestinal inflammation and the development of IBD, NF-κB signaling in epithelial cells has
been shown to promote intestinal homeostasis35–37. Our finding of a potential protective role
for NF-κB signaling is consistent with the report of Eckmann et al.38 in which ablation of
the NF-κB-activating kinase IKKβ in intestinal epithelial cells resulted in an exacerbation of
DSS-induced colitis. However, these investigators found that loss of epithelial IKKβ had no
impact on chronic colitis that occurs spontaneously in IL-10-deficient mice. Thus the
protective functions of epithelial-specific NF-κB signaling likely depend on specific
etiology of intestinal inflammation. We found that epithelial expression of the pro-
inflammatory genes TNF and IL-8 (or mouse MIP-2, a functional homolog of human IL-8)
contributed strongly to PC2. While a normal range of PC2 values is consistent with NF-κB-
stimulated physiological inflammation, high PC2 values may indicate an excessive and
damaging inflammatory response. Here we found that disease severity in acute DSS colitis
was correlated with elevated PC2 values, with no significant alterations in PC1 values.
These results are consistent with our previous findings in CD patients, where a subset of
recently-diagnosed patients with elevated PC2 values and variable PC1 values tended to
present with acute inflammation that responded well to immunosuppressive and anti-TNF
therapy16. In a recent analysis of these biomarkers in colonic biopsies of patients with UC,
we observed a similar correlation between elevated PC2 values and acute inflammation
(Bruno et al., unpublished data). These findings are significant in that many features of DSS
colitis, such as macroscopic appearance and histological injury, more closely resemble acute
inflammation in UC than CD39. In contrast, we found that some measures of disease severity
in chronic T cell-mediated colitis (weight loss, colon weight/length ratio) were correlated
with low PC1 values, whereas tissue damage in the colon was associated with high PC2
values. This pattern is similar to that observed in subsets of CD and UC patients with low
PC1 and variable PC2 values, characterized by chronic inflammation and poor responses to
immunosuppressive and anti-TNF therapy (Ref. 16 and Bruno et al., unpublished data). The
results of our current study suggest that acute colitis mediated by innate immune responses
is associated with increased epithelial expression of pro-inflammatory genes, whereas
chronic colitis driven by adaptive T cell responses is associated with diminished expression
of genes associated with homeostatic epithelial barrier function. These findings provide
insights into the role of epithelial cells in the regulation of colonic inflammation, and
support the use of these epithelial biomarkers for monitoring disease course and guiding
therapy in IBD patients. We propose that multifactorial analysis of CEC gene expression
may be valuable for monitoring the transition from acute to chronic colitis in IBD patients.
This approach may enhance our understanding of immunological mechanisms underlying
inflammation at different stages, which may require different therapeutic approaches, and
may also help to identify patients at risk for sequelae associated with chronic inflammation,
such as colitis-associated cancer.
A novel finding that emerged from this study was that expression of pIgR in CEC was
down-regulated in both acute DSS and chronic T cell colitis (Fig. 2). Furthermore, DSS-
induced inflammation was associated with reduced epithelial transcytosis of IgA (Fig. 5A).
These results were consistent with our findings in CD patients with either acute or chronic
colitis, in which expression of pIgR and transcytosis of IgA in CEC was reduced compared
to normal individuals or CD patients with mild disease16. The importance of pIgR in
prevention of intestinal inflammation is supported by the report that pIgR-deficient mice
were more susceptible to DSS-induced colitis than were wild-type mice23. pIgR transports
polymeric IgA from the basal to the apical surface of intestinal epithelial cells, where
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proteolytic cleavage of the extracellular domain of pIgR (secretory component, SC) releases
secretory IgA (SIgA) into the intestinal lumen40, 41. Because one molecule of pIgR is
synthesized for every molecule of IgA transported, the level of pIgR expression controls the
rate of epithelial transcytosis of IgA. SIgA antibodies play a critical role in shaping the
composition of the gut microbiota and in maintenance of intestinal homeostasis42. SIgA
binds to intestinal mucus via glycan-mediated interactions, thus forming an immunological
barrier to penetration of the epithelial layer by microbes and environmental antigens, and
can also neutralize antigens and microbial products intracellularly during pIgR-mediated
epithelial transcytosis. In addition, pIgR can transport IgA-containing immune complexes
across polarized IEC monolayers, thus disposing of antigens through a non-inflammatory
process 43. Thus, reduction of pIgR expression during colitis would be predicted to diminish
not only the antimicrobial function of luminal SIgA, but also removal of IgA-bound antigens
from the lamina propria. These defects would exacerbate local inflammation and increase
the level of IgA immune complexes, a potential risk factor for development of IgA
nephropathy, which has been linked with IBD44.
It should be noted that a protective role for pIgR in the T cell transfer model of colitis could
not involve transcytosis of SIgA, since B cell-deficient recipient Rag1−/− mice do not
produce IgA. However, it is well known that free SC, which is released when pIgR that is
not associated with IgA is cleaved at the apical surface of epithelial cells, contributes to
intestinal homeostasis by inhibiting bacterial adherence to the intestinal mucus layer and
neutralizing of potential pro-inflammatory factors45, 46. We found that expression of pIgR
mRNA was reduced (Fig. 2B) and the cellular localization of pIgR protein was aberrant
(Fig. 5B) in Rag1−/− mice adoptively transferred with Teff. Importantly, co-administration
of Treg prevented both of these defects. Taken together, our results suggest that
inflammation in the colon, whether due to innate immune responses in the DSS model or
adaptive immune responses in the T cell model, creates a local environment that is not
conducive to optimal expression and cellular trafficking of pIgR.
We found that epithelial expression of TNF was significantly increased in acute DSS colitis
(Fig. 2A) and contributed strongly to pro-inflammatory PC2, but not to homeostatic PC1
values (Fig. 3A). In contrast, altered epithelial expression of TNF was not a feature of T
cell-mediated chronic colitis (Fig. 2B) and contributed to both PC1 and PC2 values (Fig.
3A). Although TNF expression was not elevated in CEC of mice with T cell-mediated
colitis, we cannot rule out the possibility that production of TNF by other cell types
contributes to intestinal inflammation in this model. We previously reported that expression
of TNF in mucosal biopsies (which contain stromal and bone marrow-derived cells in
addition to epithelial cells) was actually reduced in a large subset of CD patients with
longstanding, chronic inflammation16. We recently reported that stimulation with TNF
enhances expression of pIgR through a RelA-dependent mechanism in a human CEC line 47,
suggesting that physiological production of TNF in the colonic epithelium may contribute to
intestinal homeostasis by promoting pIgR-mediated transcytosis of SIgA and innate immune
functions of SC. However, failure to regulate TNF production clearly contributes to the
pathogenesis of IBD. Biological therapies designed to neutralize TNF have been extremely
useful in managing severe colitis48, and a recent report suggests that anti-TNF therapy may
promote the activation and expansion of T regulatory cells in CD patients49. However,
neutralization of TNF can be associated with significant adverse effects, including
exacerbation of disease, serious infection and malignancies. Furthermore, anti-TNF
therapies are only effective in about half of patients, and there are as yet no clear clinical
guidelines regarding which anti-TNF drug to use first or how to manage patients who
experience recurrence of symptoms50. Our findings in CD patients and in experimental
models of colitis suggest that monitoring TNF expression in the colonic mucosa may be
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useful for understanding disease mechanisms and identifying those patients most likely to
benefit from anti-TNF therapy.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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FIGURE 1.
Assessment of disease severity in DSS and T cell transfer colitis. (A–C) DSS colitis. Mice
were left untreated or administered 2% or 3% DSS in the drinking water for 8 days. (A)
Changes in body weight (expressed as a percentage of weight at the beginning of the
experiment) and disease activity (see Materials and Methods for an explanation of the
disease activity index). Data from 1 of 3 independent experiments with similar results are
expressed as mean ± SEM (n = 8). (B) Colon lengths were measured on day 8; data
combined from 3 independent experiments are expressed as mean ± SEM (n = 16). (A,B)
One asterisk indicates that the mean is significantly different from the mean for control
mice, and two asterisks indicate that the mean is significantly different from the mean for
both control mice and mice treated with 2% DSS (p < 0.05). (C) Colon histology from
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representative mice at day 8. Images of formalin-fixed colon tissues stained with
hematoxylin and eosin were captured with a 20X objective.
(D–F) T cell transfer colitis. Rag1−/− mice were left untreated (control) or adoptively
transferred with 4 × 105 CD4+CD45RBhiCD25− T-effector cells (Teff), with or without 1 ×
105 CD4+CD45RBloCD25+ T-regulatory cells (Treg). (D) Changes in body weight; data
from 1 of 3 independent experiments with similar results are expressed as mean ± SEM (n =
8). (E) Colons were measured and weighed at 10 weeks post-transfer; data are expressed as
mean ± SEM (n = 10). (D, E) An asterisk indicates that the mean is significantly different
from the mean for control Rag1−/− mice (p < 0.05). (F) Colon histology from representative
mice at 10 weeks post-transfer. Images of formalin-fixed colon tissues stained with
hematoxylin and eosin were captured with a 20X objective.
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FIGURE 2.
Comparison of biomarker expression in colonic ECs in experimental colitis: (A) DSS colitis;
(B) T cell transfer colitis. Colitis was induced as described in Figure 1, and colonic ECs
were isolated at the end of the experiments. mRNA levels were measured by qRT-PCR and
normalized to β2-microglobulin mRNA. For each model, data from 3 independent
experiments were combined and expressed as mean ± SEM (n = 16 for DSS colitis and n =
10 for T cell transfer colitis). Asterisks indicate that the mean for treated mice is different
from the mean for control mice (p < 0.05).
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FIGURE 3.
Multifactorial analysis of biomarker expression patterns in experimental colitis, using data
described in Figure 2 for mRNA levels in colonic ECs. (A) Factor analysis was used to
reduce data for 5 variables, RelA, A20, pIgR, TNF and MIP-2, into two principal
components (PCs). Eigenvalues indicate the proportion of variance among mice in
expression of these 5 variables that can be described by PC1 and PC2. Weighted coefficients
are listed for each variable comprising PC1 and PC2. (B) PC1 and PC2 scores were
calculated for each individual mouse based on the sum of normalized expression levels for
each variable multiplied by its corresponding coefficient for PC1 and PC2 (see Materials
and Methods). Combined data from 3 independent experiments for each mouse model are
expressed as mean ± SEM (n ≤ 14 mice/group for DSS colitis and n = 10 mice/group for T
cell transfer colitis). Asterisks indicate that the mean PC values for the indicated
comparisons are significantly different (p < 0.05); NS = not significant.
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FIGURE 4.
Expression of colonic epithelial biomarkers predicts disease severity in experimental colitis:
(A) DSS colitis; (B) T cell transfer colitis. Plots depict linear regression comparing PC1 and
PC2 scores for each mouse to body weight at the end of the experiment, colon length (DSS
colitis) or the ratio of colon weight to length (T cell transfer colitis), and histological colitis
scores. Correlation coefficients (r) and P-values (p) are listed for each regression line.
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FIGURE 5.
Localization of pIgR and IgA in colonic mucosa of mice with experimental colitis: (A) DSS
colitis; (B) T cell transfer colitis. Sections of formalin-fixed colons were stained by
immunofluorescence for pIgR (green), IgA (red) and nuclei (DAPI; blue). Representative
images are shown for each treatment group. Images were captured with a 25X objective.
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